These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 15170922)

  • 1. Effects of anakinra monotherapy on joint damage in patients with rheumatoid arthritis. Extension of a 24-week randomized, placebo-controlled trial.
    Bresnihan B; Newmark R; Robbins S; Genant HK
    J Rheumatol; 2004 Jun; 31(6):1103-11. PubMed ID: 15170922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial.
    Nuki G; Bresnihan B; Bear MB; McCabe D;
    Arthritis Rheum; 2002 Nov; 46(11):2838-46. PubMed ID: 12428223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial.
    Cohen S; Hurd E; Cush J; Schiff M; Weinblatt ME; Moreland LW; Kremer J; Bear MB; Rich WJ; McCabe D
    Arthritis Rheum; 2002 Mar; 46(3):614-24. PubMed ID: 11920396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial.
    Fleischmann RM; Schechtman J; Bennett R; Handel ML; Burmester GR; Tesser J; Modafferi D; Poulakos J; Sun G
    Arthritis Rheum; 2003 Apr; 48(4):927-34. PubMed ID: 12687534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate.
    Cohen SB; Moreland LW; Cush JJ; Greenwald MW; Block S; Shergy WJ; Hanrahan PS; Kraishi MM; Patel A; Sun G; Bear MB;
    Ann Rheum Dis; 2004 Sep; 63(9):1062-8. PubMed ID: 15082469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concomitant medication use in a large, international, multicenter, placebo controlled trial of anakinra, a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis.
    Tesser J; Fleischmann R; Dore R; Bennett R; Solinger A; Joh T; Modafferi D; Schechtman J;
    J Rheumatol; 2004 Apr; 31(4):649-54. PubMed ID: 15088288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist.
    Bresnihan B; Alvaro-Gracia JM; Cobby M; Doherty M; Domljan Z; Emery P; Nuki G; Pavelka K; Rau R; Rozman B; Watt I; Williams B; Aitchison R; McCabe D; Musikic P
    Arthritis Rheum; 1998 Dec; 41(12):2196-204. PubMed ID: 9870876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial.
    Keystone EC; Kavanaugh AF; Sharp JT; Tannenbaum H; Hua Y; Teoh LS; Fischkoff SA; Chartash EK
    Arthritis Rheum; 2004 May; 50(5):1400-11. PubMed ID: 15146409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores.
    Jiang Y; Genant HK; Watt I; Cobby M; Bresnihan B; Aitchison R; McCabe D
    Arthritis Rheum; 2000 May; 43(5):1001-9. PubMed ID: 10817552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anakinra: review of recombinant human interleukin-I receptor antagonist in the treatment of rheumatoid arthritis.
    Furst DE
    Clin Ther; 2004 Dec; 26(12):1960-75. PubMed ID: 15823761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate.
    Genovese MC; Cohen S; Moreland L; Lium D; Robbins S; Newmark R; Bekker P;
    Arthritis Rheum; 2004 May; 50(5):1412-9. PubMed ID: 15146410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Durability and rapidity of response to anakinra in patients with rheumatoid arthritis.
    Schiff MH
    Drugs; 2004; 64(22):2493-501. PubMed ID: 15516150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The safety and efficacy of interleukin-1 receptor antagonist in the treatment of rheumatoid arthritis.
    Bresnihan B
    Semin Arthritis Rheum; 2001 Apr; 30(5 Suppl 2):17-20. PubMed ID: 11357167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of extended treatment with anakinra in patients with rheumatoid arthritis.
    Fleischmann RM; Tesser J; Schiff MH; Schechtman J; Burmester GR; Bennett R; Modafferi D; Zhou L; Bell D; Appleton B
    Ann Rheum Dis; 2006 Aug; 65(8):1006-12. PubMed ID: 16396977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin 1 receptor antagonist anakinra improves functional status in patients with rheumatoid arthritis.
    Cohen SB; Woolley JM; Chan W;
    J Rheumatol; 2003 Feb; 30(2):225-31. PubMed ID: 12563672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anakinra as a new therapeutic option in rheumatoid arthritis: clinical results and perspectives.
    Bresnihan B
    Clin Exp Rheumatol; 2002; 20(5 Suppl 27):S32-4. PubMed ID: 14989427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Magnetic resonance imaging for accelerated assessment of drug effect and prediction of subsequent radiographic progression in rheumatoid arthritis: a study of patients receiving combined anakinra and methotrexate treatment.
    Østergaard M; Duer A; Nielsen H; Johansen JS; Narvestad E; Ejbjerg BJ; Baslund B; Møller JM; Thomsen HS; Petersen J
    Ann Rheum Dis; 2005 Oct; 64(10):1503-6. PubMed ID: 15778238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and radiological effects of anakinra in patients with rheumatoid arthritis.
    Bresnihan B; Cobby M
    Rheumatology (Oxford); 2003 May; 42 Suppl 2():ii22-8. PubMed ID: 12817092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of ultrasonographic assessment of synovitis and joint vascularity with radiographic evaluation in a randomized, placebo-controlled study of infliximab therapy in early rheumatoid arthritis.
    Taylor PC; Steuer A; Gruber J; Cosgrove DO; Blomley MJ; Marsters PA; Wagner CL; McClinton C; Maini RN
    Arthritis Rheum; 2004 Apr; 50(4):1107-16. PubMed ID: 15077292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate.
    Maini RN; Breedveld FC; Kalden JR; Smolen JS; Furst D; Weisman MH; St Clair EW; Keenan GF; van der Heijde D; Marsters PA; Lipsky PE;
    Arthritis Rheum; 2004 Apr; 50(4):1051-65. PubMed ID: 15077287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.